Biocryst Pharmaceuticals (BCRX) Interest & Investment Income (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Interest & Investment Income data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Interest & Investment Income fell 25.4% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 million (down 27.94% YoY) and the FY2025 annual result came in at $10.7 million, down 27.65% from the prior year.
• Interest & Investment Income fell to $2.3 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $14.9 million in Q4 2023 to a low of -$808000.0 in Q3 2022.
• A 5-year average of $3.3 million and a median of $3.0 million in 2025 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 80700.0% — and 2023, when it soared 6155.56%.
• Tracing BCRX's Interest & Investment Income over 5 years: stood at $2.7 million in 2022, then jumped by 452.37% to $14.9 million in 2023, then tumbled by 76.1% to $3.6 million in 2024, then slipped by 19.05% to $2.9 million in 2025, then decreased by 21.94% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q1 2026), $2.9 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.